v3.26.1
Segment Reporting - Schedule of Operating Expenses of Our Clinical Stage Drug Development Segment (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Stock-based compensation expense $ 902,900 $ 3,448,400 $ 1,859,100 $ 7,021,200
Other Operating Segment [Member]        
Segment Reporting [Line Items]        
Clinical Study Expense 3,482,900 779,600 4,954,000 8,740,200
Other Research Expense 842,100 702,200 1,960,500 2,533,200
Manufacturing and Drug Storage Expense 2,652,500 81,600 5,436,700 237,200
Compensation Expense 836,300 1,062,700 2,510,800 1,996,100
Stock-based compensation expense 580,000 193,300 1,619,600 1,263,700
Total Research and Development Expense $ 8,393,800 $ 2,819,400 $ 16,481,600 $ 14,770,400